Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)
  7. Epidemiology and Biostatistics (153)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Surgery (123)
  10. Survivorship Research (120)
Search Within
Formats
  1. Journal Article (751)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (11)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (26)

More People

Years
  1. 2025 (40)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (412)
  2. Breast Cancer Research (67)
  3. BMC Cancer (65)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1092)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The checkpoint inhibitor TTI-621 (SIRPαFc) stimulates innate and adaptive immune responses in patients with hematologic and solid tumor malignancies
    Meeting Abstract

    Johnson, L.; Ansell, S.; Chen, R.; Flinn, I.; Maris, M.; O'Connor, O.; Lesokhin, A.; Thompson, J.; Akilov, O.; Querfeld, C.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Pre-existing T cell immunity, mutational burden and stromal TGF-β signaling drives clinical responses to atezolizumab in locally advanced or metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Mariathasan, S.; Turley, S. J.; Nickles, D.; Wang, Y.; Kadel, E. E. 3rd; Koeppen, H.; Yuen, K.; Castiglioni, A.; Astarita, J. L.; Cubas, R.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma
    Meeting Abstract

    Postow, M.; Larkin, J.; Wolchok, J.; Chiarion-Sileni, V.; Hodi, F. S.; Rutkowsk, P.; Grob, J. J.; Grossmann, K.; Schadendorf, D.; Chesney, J.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gandhi, L.; Johnson, M. L.; Opyrchal, M.; Ramalingam, S.; Janne, P.; Chachoua, A.; Ordentlich, P.; Brouwer, S.; Sankoh, S.; Schmidt, E.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Meric-Bernstam, F.; Gordon, M.; Tykodi, S.; Lam, E.; Vaishampayan, U.; Chaves, J.; Nikolinakos, P.; Fan, A.; Lee, R.; McDermott, D.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Clinical activity of adenosine 2A receptor (A2AR) inhibitor CPI-444 is associated with tumor expression of adenosine pathway genes and tumor immune modulation
    Meeting Abstract

    Hotson, A.; Powderly, J.; Emens, L.; Forde, P.; Hellman, M.; Fong, L.; Markman, B.; Hughes, B.; Goldman, J.; Sznol, M.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Identification of unique neoantigen qualities in long-term pancreatic cancer survivors
    Meeting Abstract

    Balachandran, V.; Luksza, M.; Zhao, J. N.; Makarov, V.; Moral, J. A.; Remark, R.; Herbst, B.; Askan, G.; Bhanot, U.; Senbabaoglu, Y.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Quantifying the learning curve for pulmonary thromboendarterectomy
    Journal Article

    Sihag, S.; Le, B.; Witkin, A. S.; Rodriguez-Lopez, J. M.; Villavicencio, M. A.; Vlahakes, G. J.; Channick, R. N.; Wright, C. D.
    Journal of Cardiothoracic Surgery (2017)

    Fulltext@MSK | Save
  • Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016
    Journal Article

    Ascierto, P. A.; Agarwala, S. S.; Ciliberto, G.; Demaria, S.; Dummer, R.; Duong, C. P. M.; Ferrone, S.; Formenti, S. C.; Garbe, C.; Halaban, R.; more...
    Journal of Translational Medicine (2017)

    Fulltext@MSK | Save
  • Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
    Journal Article

    Reiss, S. N.; Yerram, P.; Modelevsky, L.; Grommes, C.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save